Pediatric Endocrinology and Diabetes Unit, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv,Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
J Pediatr Endocrinol Metab. 2021 Apr 7;34(6):741-745. doi: 10.1515/jpem-2021-0172. Print 2021 Jun 25.
The benefits of gonadotropin-releasing hormone analogues (GnRHa) in the treatment of central precocious puberty are well established, and their use is regarded as both safe and effective. Possible adverse effects on blood pressure (BP) and cardiac outcomes, body composition, bone health and brain development, however, continue to be of some concern. The aim of this study was to analyze BP changes in transgender female adolescents before and after receiving GnRHa and after adding estrogen treatment.
This was a retrospective pilot study. We analyzed systolic BP (SBP) and diastolic BP (DBP) before and after GnRHa initiation and after adding estrogen.
Nineteen transgender female adolescents received GnRHa and 15 continued to estrogen treatment. Their baseline SBP and DBP percentiles did not change significantly after either GnRHa or the addition of estrogen treatment.
Blood pressure is apparently not affected by GnRHa or GnRHa + estrogen treatment in transgender female adolescents. Further larger studies are indicated to confirm these findings.
促性腺激素释放激素类似物（GnRHa）在治疗中枢性性早熟中的益处已得到充分证实，其应用被认为既安全又有效。然而，其对血压（BP）和心脏结局、身体成分、骨骼健康和大脑发育的潜在不良影响仍令人关注。本研究旨在分析接受 GnRHa 治疗前后以及添加雌激素治疗后 transgender 女性青少年的血压变化。
这是一项回顾性试点研究。我们分析了 GnRHa 起始前、后和添加雌激素后的收缩压（SBP）和舒张压（DBP）。
19 名 transgender 女性青少年接受了 GnRHa 治疗，15 名继续接受雌激素治疗。无论是 GnRHa 还是添加雌激素治疗后，他们的基线 SBP 和 DBP 百分位数均无明显变化。
GnRHa 或 GnRHa+雌激素治疗似乎不会影响 transgender 女性青少年的血压。需要进一步开展更大规模的研究来证实这些发现。
